Global Cell Therapy Human Raw Materials Market to Reach USD 18.94 Billion by 2035

Industry
โดย Healthcare Foresights·Read original
Summary · why it matters

The global cell therapy human raw materials market is projected to grow from USD 3.62 billion in 2025 to USD 18.94 billion by 2035, at a compound annual growth rate of 16.3% during the forecast period from 2026 to 2035, according to a report by Healthcare Foresights. The market was valued at approximately USD 3.62 billion in 2025 and is expected to reach USD 4.21 billion in 2026. Key players include Thermo Fisher Scientific, Merck KGaA (MilliporeSigma), Sartorius AG, and others. Growth is driven by increasing cell therapy clinical trials and approvals, rising prevalence of cancer and chronic diseases, and advancements in GMP-compliant, xeno-free, and serum-free formulations. North America dominated the market in 2025, while the Asia Pacific region is expected to show the fastest growth.

Impact on stocks 4

Biotech & Genomic Medicine▲ · 2 stocks
Sartorius Stedim Biotech SA
DIM
▲ PositiveDemandrelevance

Market growth driven by increasing cell therapy clinical trials and approvals, boosting demand for raw materials supplied by Sartorius Stedim Biotech.

Thermo Fisher Scientific Inc
TMO
▲ PositiveDemandrelevance

Market growth driven by increasing cell therapy clinical trials and approvals, boosting demand for raw materials supplied by Thermo Fisher.

Critical Materials & Supply Chain▲ · 1 stocks
Merck KGaA
MRK
▲ PositiveDemandrelevance

Market growth driven by increasing cell therapy clinical trials and approvals, boosting demand for raw materials supplied by Merck KGaA.

Health Care▲ · 1 stocks
Sartorius Aktiengesellschaft
SRT3
▲ PositiveDemandrelevance

Market growth driven by increasing cell therapy clinical trials and approvals, boosting demand for raw materials supplied by Sartorius AG.

Theme Impact 1

Related news

Avantor Expands RIM Single-Use Bioprocessing Portfolio Across APAC

Avantor has expanded the availability of its RIM single-use bioprocessing portfolio across the Asia Pacific region, strengthening its presence in a key biopharma manufacturing market. The portfolio includes single-use consumables such as bioprocessing bags, assemblies, tubing and components, plus mixing and storage hardware, and is manufactured at Avantor's Changzhou, China facility, the company's first single-use production site in APAC. That 2,600-square-meter plant operates under ISO 9001:2015 certification and Good Manufacturing Practice standards, and RIM products are available exclusively to APAC customers. The move aligns with management's broader Revival strategy, and in the second quarter of 2026 the Bioscience & Medtech Products segment posted double-digit order growth and a book-to-bill ratio of 1.1x, with management expecting the segment to return to organic growth in the second half of 2026. Avantor currently has a market capitalization of $10.56 billion, and its shares have gained 38.4% year to date versus 3.4% growth for the industry and a 10.1% rise in the S&P 500.
AVTR ▲
Biotech & Genomic Medicine
Zacks Investment Research·1dRead more →
▲

Andelyn Begins Commercial Manufacturing of Ultragenyx's FDA-Approved FAYUVI Gene Therapy

Andelyn Biosciences announced it is now manufacturing FAYUVI, Ultragenyx Pharmaceutical Inc.'s FDA-approved gene therapy for Sanfilippo syndrome type A, also known as mucopolysaccharidosis type IIIA, for commercial supply at its Columbus, Ohio facility. The move follows the U.S. Food and Drug Administration's approval of FAYUVI, making it the first FDA-approved gene therapy manufactured using the Andelyn AAV Curator Platform process. Sanfilippo syndrome type A is a rare, fatal lysosomal storage disease that primarily affects the central nervous system and is marked by rapid neurodegeneration beginning in early childhood; it is estimated to affect 3,000 to 5,000 patients worldwide, with a median life expectancy of 15 years. Andelyn Chief Executive Officer Wade Macedone said the company is proud to manufacture an FDA-approved gene therapy for commercial use using an AAV Curator Platform process, calling the milestone a reflection of the purpose behind Andelyn's founding. Andelyn, a full-service FDA-inspected cell and gene therapy commercial CDMO with more than 20 years of experience, has produced clinical and commercial material for more than 500 cGMP batches and 85 global clinical trials.
RARE ▲
Biotech & Genomic Medicine ▲
PR Newswire·1dRead more →
▲2

Charles River Laboratories Launches Rapid Cell Banking Platform With 40% Faster Production

Charles River Laboratories International unveiled new rapid cell banking and release programs that use advanced sequencing and in vitro tools to shorten biologics and advanced therapy cell bank lead times for biopharma clients. The platform cuts cell bank production time by 40% and combines rapid microbiological methods with NGS characterization, including the iDTECT NGS platform, to support regulatory readiness. Charles River says the approach reduces reliance on animal testing by incorporating alternative in vitro methods aligned with the 3Rs framework. The company, a US life sciences group with a market cap of about $13.1b, positions the offering for time-sensitive programs where delays are costly. Investors will watch for booked projects using the iDTECT NGS platform, client mix in advanced therapies, and whether the services appear in updated segment revenue breakdowns.
CRL
Biotech & Genomic Medicine ▲
Simply Wall St·1dRead more →
© 2026 MarketDXNews